Piper Sandler slashes price target on ImmunityBio Inc [IBRX] – find out why.

ImmunityBio Inc [NASDAQ: IBRX] stock went on a downward path that fall over -0.55% on Thursday, amounting to a one-week price decrease of less than -13.37%. The company report on January 2, 2024 at 6:00 AM that ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million.

Up to $300 million non-dilutive capital exchanged for royalty payments on future ImmunityBio immunotherapy product revenue with up to a $20 million equity investment.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Royalty financing includes $200 million funded at closing, and $100 million to be funded contingent upon FDA approval of the Company’s BLA for Anktiva® in combination with BCG for NMIBC with PDUFA date of April 23, 2024.

Over the last 12 months, IBRX stock dropped by -23.42%. The one-year ImmunityBio Inc stock forecast points to a potential upside of 9.25. The average equity rating for IBRX stock is currently 3.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $2.42 billion, with 421.57 million shares outstanding and 130.82 million shares in the current float. Compared to the average trading volume of 6.25M shares, IBRX stock reached a trading volume of 3493215 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on ImmunityBio Inc [IBRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 12, 2023.

The Average True Range (ATR) for ImmunityBio Inc is set at 0.37, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 4328.19.

IBRX Stock Performance Analysis:

ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.37. With this latest performance, IBRX shares dropped by -15.58% in over the last four-week period, additionally plugging by 17.10% over the last 6 months – not to mention a drop of -23.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 39.58, with the RSI for the last a single of trading hit 30.80, and the three-weeks RSI is set at 44.85 for ImmunityBio Inc [IBRX]. The present Moving Average for the last 50 days of trading for this stock 4.03, while it was recorded at 3.77 for the last single week of trading, and 2.75 for the last 200 days.

Insight into ImmunityBio Inc Fundamentals:

ImmunityBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.38 and a Current Ratio set at 2.38.


With the latest financial reports released by the company, ImmunityBio Inc posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -21.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc go to -1.70%.

ImmunityBio Inc [IBRX] Institutonal Ownership Details

The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in IBRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in IBRX stock with ownership which is approximately 5.8325%.